IBCG shared a post on X:
“IBCG is pleased to welcome Dr. Amir Horowitz, PhD, to our Scientific Advisory Board. Dr. Horowitz is an Associate Professor of Immunology and Immunotherapy and Oncological Sciences, and a faculty member of the Tisch Cancer Institute and the Marc and Jennifer Lipschultz Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai.
Dr. Horowitz is internationally recognized for his studies of human Natural Killer (NK) cells and CD8 T cells and his team’s science-based translational studies for overcoming resistance to frontline therapies in patients with bladder cancer.
Through this role with the IBCG SAB, Dr. Horowitz will bring knowledge of cancer immunology, including but not limited to tumor biomarker studies and contribute to initiatives that support IBCG’s mission of improving outcomes for patients worldwide by developing real-world, evidence-based solutions, shaping consensus recommendations that guide clinical practice, and fostering global collaborations that unite clinicians, researchers, and patient advocates across disciplines and continents.”
More posts featuring Amir Horowitz on OncoDaily.